Full Title: Elevated plasma cortisol associated with larger ventricles and smaller hippocampal volumes – a study in 2 independent elderly cohorts

Short Title: Cortisol, larger ventricles and smaller hippocampal volumes

Authors: Priya Rajagopalan¹, Kwangsik Nho², Shannon L. Risacher², Neda Jahanshad³, Christina P. Boyle³, Andrew J. Saykin^{2*}, Paul M. Thompson^{3*}

*Senior authors AJS and PMT jointly supervised the work.

¹ University of California San Francisco, Department of Radiology and Biomedical Imaging, San Francisco, CA, USA

² Indiana University, Department of Radiology and Imaging Sciences, Indianapolis, IN, USA

³ Imaging Genetics Center, Mark & Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Corresponding author: Priya Rajagopalan (priya.rajagopalan@ucsf.edu, prdr1723@gmail.com)

Present address: 505 Parnassus avenue, Room L352, San Francisco, CA 94143

Total character count: 26/30 doubled-spaced pages, including references, figures and tables) including only the most essential figures and table for Neurobiology of Aging

Abstract: 170/170 words

Number of Display Items: 4 (3 Figures and 1 Table)

References: 60

Highlights:

- Elevated cortisol associated with larger ventricular volumes and smaller hippocampal volumes
- Associations are predominantly noted in the right cerebral hemisphere.
- Similar non-significant trends noted in amygdalar volumes
- Cortisol and stress reducing strategies may halt brain changes and improve quality of life
- Imaging biomarkers may help assess efficacy of cortisol-lowering therapeutic interventions

Keywords:

Cortisol, brain volumes, hippocampus, amygdala, lateral ventricles, stress

Conflicts of Interest: **AJS** received collaborative research support from Eli Lilly and PET tracer precursor from Avid Radiopharmaceuticals, served as a consultant to Bayer Oncology, held an SBIR grant with Arkley BioTek, and received Editorial Office support from Springer-Nature as Editor in Chief of Brain Imaging and Behavior, all unrelated to this manuscript. **PMT** and **NJ** are MPI for a research grant from Biogen, Inc. (Boston, USA) for research unrelated to this manuscript. None of the other co-authors has any relevant disclosures.

Funding: **PR** was supported by Radiological Society of North America Resident Research Grant, 2017-2018. **KN** is supported by NLM R01 LM012535, R03 AG063250, and NIA R03

AG054936. NJ is additionally supported by R01AG059874. **AJS** is supported by NIA P30 AG010133, NIA K01 AG049050, NIA R01 AG061788, and NIA R01 AG19771. **PMT** is supported by U54 EB020403, P41 EB015922, P01 AG026572, P01 AG055367, RF1 AG051710, R01 AG060610, and R56 AG058854 to the ENIGMA World Aging Center.

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Abstract

Cortisol is considered the most fundamental stress hormone and is elevated in stress and multiple neuropsychiatric conditions. Prior studies have shown associations of plasma cortisol levels with total cerebral and hippocampal volumes and less consistently with the amygdala. Here, we extend our hypothesis to test associations of plasma cortisol with 1) ventricular 2) hippocampal and 3) amygdalar volumes, in two independent elderly cohorts across a broad cognitive spectrum ranging from normal cognition to Alzheimer's disease.

We demonstrate elevated cortisol to be associated with larger lateral ventricular volumes and smaller hippocampal volumes, predominantly in the right cerebral hemisphere, regardless of age, sex or cognitive status. We noted a non-significant trend of smaller amygdalar volumes with elevated cortisol.

Our findings support smaller brain parenchyma volumes seen with elevated cortisol and may encourage effective strategies reducing cortisol and stress. They may also serve as imaging biomarkers for assessing therapeutic benefits of stress and cortisol lowering interventions aiming to halt or reverse the brain volume alterations and theoretically improve cognition and quality of life.

1. Introduction

Stress is an inevitable challenge in everyday life. Typically, the human body responds to stressful stimuli by triggering the release of cortisol into the bloodstream through activation of the hypothalamic-pituitary-adrenal (HPA) axis, which facilitates restoration of homeostasis. Cortisol, a corticosteroid hormone, is considered a reliable indicator of HPA activity and is the most fundamental stress hormone. Excessive and sustained production of cortisol can cause malfunctioning of the HPA feedback loop, leading to symptoms of physiological and psychological distress (Chrousos and Gold, 1992; Le Fevre et al., 2003), all of which can increase morbidity and mortality (Pratt, 2009).

While cortisol levels increase with physiological aging (Ferrari et al., 1995; Ferrari et al., 2004), multiple neuropsychiatric conditions demonstrate elevated cortisol levels irrespective of age. For example, cortisol levels are higher than normal in conditions such as schizophrenia, bipolar disorder (Gallagher et al., 2007; Ryan et al., 2004), major depression (Linkowski et al., 1987; Plotsky et al., 1995) and Alzheimer's disease (Davis et al., 1986; Martignoni et al., 1990). Within these conditions, cortisol levels are higher in those with a greater degree of cognitive impairment (Hinterberger et al., 2013; Zvěřová et al., 2013).

The limbic system of the brain, including the hippocampus and amygdala, has abundant corticosteroid receptors, making it a principal target for increased vulnerability to prolonged cortisol exposure. There are two main kinds of corticosteroid receptors expressed in the brain, most notably in the hippocampus, called type I mineralocorticoid receptors with permissive effects and type II glucocorticoid receptors with suppressive effects (de Kloet et

al., 2005; Sapolsky, 1996). The hippocampus is involved in the consolidation and retrieval of declarative memory, whereas the amygdala supports affective and emotional aspects of cognition (Pruessner et al., 2010). These are both important structures for HPA axis regulation. The hippocampus is primarily inhibitory and exerts a negative feedback on the HPA axis after termination of a stressful stimulus, whereas the amygdala is predominantly excitatory in nature.

Neuroimaging studies have found elevated plasma cortisol levels to be associated with smaller hippocampi in AD (De Leon et al., 1988; Huang et al., 2009) and in cognitively healthy older adults (Lupien et al., 1998). Plasma cortisol levels have also been shown to be associated with smaller total cerebral brain volumes in healthy middle aged women, but not in men of middle-age (Echouffo-Tcheugui et al., 2018) or older ages (MacLulich et al., 2005). Additionally, evening but not morning, salivary cortisol levels were shown to be associated with smaller total brain, gray and white matter volumes in older adult participants without dementia (Geerlings et al., 2015).

Both hippocampi and amygdala demonstrate increased glucocorticoid receptors in hypercortisolemic neuropsychiatric conditions such as major depressive disorder (Wang et al., 2012; Wang et al., 2014) and brain volume reductions have been reported in early onset depression (Janssen et al., 2004; Schmaal et al., 2016). While stress and hypercortisolemic neuropsychiatric diseases have consistently shown smaller hippocampi (Pruessner et al., 2010; Sapolsky, 1996; Swaab et al., 2005), the volumetric associations for the amygdala

however have been inconsistent (Kronenberg et al., 2009; Malykhin et al., 2018; Mervaala et al., 2000; Mitra et al., 2005; Pruessner et al., 2010).

In this study, we investigated the association of plasma cortisol levels with region of interest (ROI)-based subcortical volumes in two independent cohorts of older adults across a broad cognitive spectrum, including normal cognition (CN), mild cognitive impairment (MCI), and Alzheimer's disease (AD). We focused on established neuroimaging markers for neuropsychiatric disorders such as AD, including lateral ventricular, hippocampal and amygdalar volumes (Hendren et al., 2000).

2. Materials and methods

The study was conducted according to the Good Clinical Practice guidelines, the Declaration of Helsinki, and US 21 CFR Part 50 — Protection of Human Participants and Part 56 — Institutional Review Boards in the two cohorts, namely the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS). All study participants gave written informed consent.

2.1 ADNI - Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu/>). ADNI is a multisite study that includes older adults across a spectrum of cognitive impairment; each participant was assessed with at least one 1.5 tesla anatomical brain MRI scan, blood sampling, and cognitive and clinical testing at one of 58 sites across North America. Inclusion and exclusion criteria for ADNI are detailed online at <http://adni.loni.usc.edu> (Mueller et al.,

2005). The present analysis was carried out in a total of 487 non-Hispanic White participants (average age: 75.13 +/- 0.3 years; 301 males and 186 females; 107 with AD, 332 with MCI and 48 CN) with brain MRI and plasma cortisol data.

2.2 IMAS – The Indiana Memory and Aging Study (IMAS) is a regional cohort, based in Indianapolis, Indiana, which includes older adults across a broad cognitive spectrum. The selection criteria and characterization have been described previously (Kim et al., 2013; Risacher et al., 2013; Saykin et al., 2006). All participants underwent a 3D T1-weighted MPRAGE brain scan on a Siemens TIM Trio 3T scanner, as well as collection of blood samples, and extensive cognitive and clinical testing. The analysis was performed in a total of 54 non-Hispanic White participants (average age: 72.57 +/- 0.98 years; 19 males and 35 females; 6 with AD, 21 with MCI and 27 CN) who had plasma cortisol and brain MRI data.

2.3 MRI acquisition

The T1-weighted 1.5 T structural brain MPRAGE scans were acquired at multiple ADNI sites with a standardized protocol (Jack et al., 2010). The T1-weighted 3T structural brain MRI scans were acquired for the IMAS participants following the ADNI protocol.

2.4 Regional brain volumes

For the analysis, total intracranial volumes, left and right lateral ventricular, hippocampal, and amygdalar volumes (in mm³) were extracted from MRI scans for both ADNI and IMAS participants using the FreeSurfer image analysis suite, version 5.1 (<http://surfer.nmr.mgh.harvard.edu/>; (Fischl et al., 2002)).

2.5 Morning plasma cortisol levels

Plasma cortisol exhibits a circadian rhythmicity with highest levels being secreted in the morning (Chida and Steptoe, 2009). In ADNI, plasma cortisol levels were obtained from morning blood samples collected at the time of MRI scan (http://www.adni-info.org/Scientists/Pdfs/14-Biomarker_Sample_Collection_Processing_and_Shipment.pdf) using the ‘Human Discovery Multi-Analyte Profile’ platform by Myriad Rules-Based Medicine (RBM, www.rulesbasedmedicine.com, Austin, TX). The quantification method is described in the document ‘Biomarkers Consortium ADNI Plasma Targeted Proteomics Project – Data Primer’ (http://adni.loni.usc.edu/wp-content/uploads/2010/11/BC_Plasma_Proteomics_Data_Primer.pdf). Plasma cortisol assessment for the IMAS mirrored the ADNI protocol and has been described previously (Kim et al., 2013).

Theoretically, altered HPA axis activity with artificially low cortisol levels may result from including steroid containing oral medications and intra-articular injections (Habib, 2009; Hengge et al., 2006; Lipworth, 1999). Therefore, after reviewing the medication history in detail, 30 of the 517 (5.8%) participants from ADNI with steroid usage (oral, injection and inhalational route of usage) were identified and excluded from the final analysis which was performed in 487 participants. Of note, the inclusion or exclusion of these participants in the reported analyses did not alter the pattern of significant results (data not presented here). Similarly, 4 of 58 (6.9%) of the IMAS participants were excluded for usage of steroids and the final analysis was performed in 54 participants.

2.6 Statistical analysis

To reduce skewness in the plasma cortisol concentrations, we carried out a logarithmic transformation of the cortisol measure using the natural logarithmic transformation (**Figure 1**).

Using linear regression performed in the *Stata* (StataCorp, 2011, College Station, Texas) software package, we modeled the effect of cortisol measures (**Equation 1**) on left and right lateral ventricular, hippocampal and amygdalar volumes (in mm³), in both the ADNI and IMAS cohorts. The association of plasma cortisol levels with brain subcortical volumes was first assessed in ADNI (**Table 1a**) and tested for replication in IMAS (**Table 1b**). An additional *post-hoc* mega-analysis was carried out by combining both ADNI and IMAS participants (**Table 1c**).

$$\text{Brain volumes} = \beta_0 + \beta_1 \text{Cortisol} + \beta_2 \text{Age} + \beta_3 \text{Sex} + \beta_4 \text{Diagnosis} + \beta_5 \text{Intracranial Volume} + \epsilon$$

Equation 1: Linear regression model used in the study

All

associations were adjusted for predictors regarded as potential confounders, including age, sex, total intracranial volume and diagnosis (AD, MCI or CN). Age and sex were known confounders affecting the HPA axis and the HP gonadal axis, with studies demonstrating an accentuated cortisol response in older women (Otte et al., 2005). We adjusted for total

intracranial volume to eliminate confounding effects from variation in head size. Covariates include diagnostic status of AD, MCI or CN to eliminate the known association of hypercortisolism with AD (Davis et al., 1986; Martignoni et al., 1990) and cognition (Echouffo-Tcheugui et al., 2018).

As the six imaging phenotypes (left and right ventricular, left and right hippocampal and left and right amygdalar volumes) strongly correlate with each other, we applied principal component analysis to estimate the number of independent principal components (PC) and to adjust for multiple testing with Bonferroni correction. Two PCs were found to be significant (with an eigenvalue > 1) and these components explained 87% of the variation of the six regions of interest. Thus, an association with $p\text{-value} < 0.025$ ($0.05/2$) was considered as significant. Volumetric regression analysis of cortisol histogram plots and regional brain volumes and were created using *Stata*.

3. Results

Of the 487 ADNI participants (average age: 75.13 $\pm$ 0.3 years; 301 males and 186 females), 107 were diagnosed with AD, 332 with MCI and 48 were CN. Of the 54 IMAS participants (mean age: 72.57 $\pm$ 0.98 years; 19 males and 35 females), 6 were diagnosed with AD, 21 with MCI and 27 were CN.

The mean and standard deviation of logarithmically transformed cortisol levels in the ADNI cohort were 2.17 $\pm$ 0.13. logarithmic units (2.20 $\pm$ 0.11 in AD, 2.16 $\pm$ 0.13 in MCI and 2.17 $\pm$ 0.15 in CN) whereas in IMAS cohort were 2.80 $\pm$ 0.15 logarithmic units (2.20 $\pm$ 0.11 in

AD, 2.16 +/- 0.13 in MCI and 2.17 +/- 0.15 in CN). Histogram plots with overlaid normal curves for cortisol levels are demonstrated for both cohorts in **Figure 1**.

Higher plasma cortisol measures were associated with significantly larger right lateral ventricular volumes ($p=0.016$) in ADNI (**Table 1a & Figures 2b**) and in a mega-analysis combining ADNI and IMAS participants ($p=0.006$) (**Table 1c**), with similar non-significant trends noted in the smaller IMAS cohort ($p=0.048$) (**Table 1b & Figure 3b**). Both ADNI and IMAS cohorts demonstrated similar but non-significant trends of larger left ventricular volumes associated with elevated cortisol.

In ADNI participants, elevated cortisol levels were associated with significantly smaller right hippocampal ($p=0.02$) and left hippocampal volumes ($p=0.017$) (**Table 1a, Figure 2c, 2d**). In a mega-analysis combining ADNI and IMAS participants right hippocampal volumes continued to be significantly associated ($p=0.042$) (**Table 1c**), with similar but non-significant trends demonstrated in the smaller IMAS cohort (**Table 1b & Figure 3d**).

Smaller right amygdalar volumes ($p=0.035$) were noted in ADNI participants but did not meet Bonferroni significance criteria of $p<0.025$. Both ADNI and IMAS cohorts demonstrated similar but non-significant trends of smaller amygdalar volumes associated with elevated cortisol (**Tables 1a, 1b, 1c & Figures 2, 3**).

The lack of significance in IMAS is potentially attributable to inadequate power owing a much smaller sample size. An additional *post hoc* mega-analysis (**Table 1c**) was performed

after combining ADNI and IMAS participants, which revealed elevated cortisol levels to be significantly associated with larger ventricular volumes and smaller hippocampal volumes, both noted in the right hemisphere.

4. Discussion

We found a significant association between elevated cortisol and smaller regional brain volumes, in an asymmetric pattern, with significant associations detected predominantly in the right hemisphere. Specifically, we demonstrated associations between elevated cortisol levels and larger lateral ventricular volumes and smaller hippocampal volumes, with similar but non-significant trends in the smaller IMAS cohort.

4.1 Ventricular volumes

In line with our hypothesis, increasing plasma cortisol was associated with significantly larger ventricular volumes, predominantly in the right hemisphere, in ADNI with similar non-significant trends in IMAS data. This may reflect underlying decreased periventricular white matter volumes and generalized atrophy, as can be expected based on prior studies in hypercortisolemic neuropsychiatric disorders such as bipolar disorder and schizophrenia. For example, salivary cortisol is known to affect periventricular white matter structural integrity in healthy controls and euthymic and bipolar patients (Macritchie et al., 2013) and larger ventricular volumes have been noted in patients with schizophrenia (Johnstone et al., 1976; van Erp et al., 2016).

4.2 Hippocampal structural change - atrophy versus re-modeling

We found significantly smaller hippocampal volumes associated with elevated cortisol, as expected based on prior literature on cortisol or hypercortisolemic neuropsychiatric conditions. Hippocampi demonstrate increased glucocorticoid receptor expression in major depressive disorder (Wang et al., 2012). Although the animal literature supports glucocorticoid-mediated neurotoxicity and apoptosis (Sapolsky, 1996), the idea of attributing cortisol-associated brain volume loss to permanent neuronal death has been called into question by human neuropathological studies, which favor the idea that brain structural changes associated with abnormally high cortisol may represent a combination of shrinkage of the neuronal soma, loss of dendritic branching, decreased adult neurogenesis, promotion of oligodendrogenesis and not necessarily neuronal cell death (Chetty et al., 2014; Curtis et al., 2007; McEwen, 2012; Swaab et al., 2005). Additionally, lower hippocampal volumes but higher neuronal density, suggestive of shrinkage and changes in neuropil, has been noted in major depression (Cobb et al., 2013).

4.3 Amygdalar changes

The amygdalar associations did not pass the Bonferroni significance cut off $p\text{-value} < 0.025$. However, we noticed with similar trends in both ADNI and IMAS cohorts, with smaller amygdalar volumes associated with elevated cortisol. Animal literature typically shows the amygdala to be a very plastic structure (Carrillo et al., 2007), with volumetric associations inconsistently noted in stress and hypercortisolemia-associated neuropsychiatric conditions, such as depression. For example, increased spine density of the basolateral amygdala was found in rats with stress (Mitra et al., 2005) and larger volumes of centromedial amygdala were noted in progressive major depressive disorder (Malykhin et al., 2018). On the other

hand, smaller amygdala were seen in women with severe depression (Mervaala et al., 2000), unipolar depression (Kronenberg et al., 2009), major depressive disorder (Schmaal et al., 2016) and after chronic corticosteroid therapy (Brown et al., 2008).

4.4 Strengths and limitations

Strengths of our study include: (i) two well-described cohorts of older adult participants with a broad range of cognitive functioning, (ii) well-validated brain volume quantification methods for regional brain volumes (<http://surfer.nmr.mgh.harvard.edu/>), and (iii) adjustments for cognitive diagnosis allowing us to identify brain structural differences beyond those that translated into a cognitive deficit.

Limitations of the study include: (i) inclusion of only Caucasian participants, limiting generalizability to other ethnic groups, (ii) correlational nature of the cortisol study, as the causal direction behind HPA axis activation and brain volume loss cannot be determined clearly and is beyond the scope of this study, (iii) plasma cortisol was measured as part of a multiplex proteomic study, which may affect the sensitivity and variance of cortisol measurements, (iv) lack of a salivary cortisol measure, which has been advocated to avoid venipuncture associated stress effects and corticosteroid binding globulin associated variations on plasma cortisol measures (Gallagher et al., 2006).

Unfortunately, we were limited by the data available in ADNI and IMAS, which have a somewhat broad focus on discovering novel biomarkers for AD, and as such, collected a large variety of health measures, making it impractical to adhere to the strict standard

sampling protocols used in some studies that focus specifically on HPA. Participants may have experienced some anxiety associated with undergoing MRI scanning and blood sample collection through venipuncture, and this anxiety may increase cortisol levels (Tessner et al., 2006). Even so, such an effect, if present, is unlikely to cause any systematic association of cortisol levels with brain volumes across a large sample. Due to these factors, the real strength of the association between cortisol and lower brain volume may have been underestimated in our study.

4.5 Future Potential

We used well-established imaging markers for stress and neuropsychiatric disorders, such as hippocampal and ventricular volumes. We would like to extend the analysis to explore every single voxel in the brain using a more unbiased approach and test the cortisol associations in both a cross-sectional and longitudinal pattern in the future.

Smaller cerebral volumes associated with elevated cortisol and stress have been shown to be reversible after correction of the hypercortisolism in Cushing's syndrome (Bourdeau et al., 2002; Starkman et al., 1992) and after long-term recovery in anorexia nervosa (Wagner et al., 2006), suggestive of neuronal plasticity, survival and recovery after cortisol level normalization. Our study therefore encourages development of non-invasive stress and cortisol reduction strategies including meditation to reduce its detrimental effects on brain (Cahn and Polich, 2006).

Yoga and long-term meditation have demonstrated increased and volumes for the right cerebral cortex (Lazar et al., 2005), implicating its ability to potentially slow cognitive decline and degeneration. Prior animal studies have shown chronic antidepressant use to

increase neurogenesis (Malberg et al., 2000), providing a strong impetus for future research involving therapeutic strategies for neurogenesis to counter the brain volume loss, such as progenitor cell transplantation, transcription factor therapy and viral implantation (Curtis et al., 2007; Martignoni et al., 1990).

5. Conclusion:

Our study offers a useful contribution to the literature by offering further support to the theory of cortisol mediated alterations in brain parenchymal volumes. We demonstrated higher plasma cortisol was associated with larger ventricular and smaller hippocampal volumes, predominantly in the right hemisphere, regardless of age, sex or cognitive status. These brain volume changes could affect normal brain function including cognition and affect quality of life in people affected with various neuropsychiatric conditions. Our findings 1) encourage development of effective stress and cortisol reduction strategies to decrease its detrimental effects on brain and 2) offer non-invasive imaging biomarkers to test efficacy of such future therapeutic clinical trials aiming to halt or reverse the progress of volume alterations.

Figure 1. Logarithmic transformation of plasma cortisol measures using the natural logarithm was carried out to reduce skewness of the data in both cohorts.

Figure 2: In ADNI, elevated cortisol was associated with greater (a) left lateral ventricular ($p=0.07$) and (b) right lateral ventricular ($p=0.016^*$) volumes, as well as lower (c) left hippocampal ($p=0.02^*$), (d) right hippocampal ($p=0.017^*$), (e) left amygdalar ($p=0.273$) and (f) right amygdalar ($p=0.035$) volumes, after adjusting for effects of age, sex, intracranial volumes and diagnosis (AD, MCI or CN) and using a Bonferroni corrected $P < 0.025$.

Figure 3: In IMAS, elevated cortisol was associated with non-significant but similar trends of greater (a) left lateral ventricular and (b) right lateral ventricular volumes, as well as lower (c) left hippocampal, (d) right hippocampal, (e) left amygdalar and (f) right amygdalar volumes, after adjusting for effects of age, sex, intracranial volumes and diagnosis (AD, MCI or CN).

Table 1. (a) Linear regression analysis demonstrates a significant association of cortisol levels with ventricular and hippocampal volumes in older adults in the ADNI cohort, based on PC analysis adjusted Bonferroni-corrected P-value of <0.025 considered significant. (b) There were non-significant but similar trend of associations noted in the much smaller IMAS cohort. (c) A mega-analysis combining both ADNI and IMAS data demonstrated significant association of cortisol levels with ventricular and hippocampal volumes, using a P-value < 0.05. All associations were adjusted for effects of age, sex and diagnosis (AD, MCI, or CN). Significant P-values are denote by *.

a) ADNI (n=487)	Beta (mm ³ /log	SE	P
-----------------	----------------------------	----	---

	unit cortisol)		
Left lateral ventricle	5501.094	3031.037	0.07
Right lateral ventricle	6597.851	2720.709	0.016*
Left hippocampus	-379.6495	162.0562	0.02*
Right hippocampus	-434.7579	181.1752	0.017*
Left amygdala	-84.77362	77.25761	0.273
Right amygdala	-164.6696	77.96728	0.035

b) IMAS (n=54)	Beta	SE	P
Left lateral ventricle	11761.82	6601.119	0.081
Right lateral ventricle	13560.43	6680.916	0.048
Left hippocampus	-38.74605	516.336	0.941
Right hippocampus	-432.4121	498.0105	0.39
Left amygdala	-138.9179	317.6539	0.664
Right amygdala	-293.4055	261.1924	0.267

c) Mega-analysis (n=541)	Beta	SE	P
Left lateral ventricle	5510.943	2779.744	0.048
Right lateral ventricle	6893.685	2506.007	0.006*
Left hippocampus	-256.2354	155.1066	0.099
Right hippocampus	-346.9274	169.9942	0.042*
Left amygdala	-23.38596	78.21476	0.765
Right amygdala	-133.4573	75.60105	0.078

References

- Bourdeau, I., Bard, C., Noel, B., Leclerc, I., Cordeau, M.P., Belair, M., Lesage, J., Lafontaine, L., Lacroix, A., 2002. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. *J Clin Endocrinol Metab* 87(5), 1949-1954.
- Brown, E.S., Woolston, D.J., Frol, A.B., 2008. Amygdala volume in patients receiving chronic corticosteroid therapy. *Biol Psychiatry* 63(7), 705-709.
- Cahn, B.R., Polich, J., 2006. Meditation states and traits: EEG, ERP, and neuroimaging studies. *Psychol Bull* 132(2), 180-211.
- Carrillo, B., Pinos, H., Guillamón, A., Panzica, G., Collado, P., 2007. Morphometrical and neurochemical changes in the anteroventral subdivision of the rat medial amygdala during estrous cycle. *Brain research* 1150, 83-93.
- Chetty, S., Friedman, A., Taravosh-Lahn, K., Kirby, E., Mirescu, C., Guo, F., Krupik, D., Nicholas, A., Geraghty, A., Krishnamurthy, A., 2014. Stress and glucocorticoids promote oligodendrogenesis in the adult hippocampus. *Molecular psychiatry* 19(12), 1275-1283.
- Chida, Y., Steptoe, A., 2009. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. *Biological psychology* 80(3), 265-278.
- Chrousos, G.P., Gold, P.W., 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. *Jama* 267(9), 1244-1252.
- Cobb, J.A., Simpson, J., Mahajan, G.J., Overholser, J.C., Jurjus, G.J., Dieter, L., Herbst, N., May, W., Rajkowska, G., Stockmeier, C.A., 2013. Hippocampal volume and total cell numbers in major depressive disorder. *J Psychiatr Res* 47(3), 299-306.
- Curtis, M.A., Kam, M., Nannmark, U., Anderson, M.F., Axell, M.Z., Wikkelsø, C., Holtas, S., van Roon-Mom, W.M., Bjork-Eriksson, T., Nordborg, C., Frisen, J., Dragunow, M., Faull, R.L., Eriksson, P.S., 2007. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. *Science* 315(5816), 1243-1249.

Davis, K.L., Davis, B.M., Greenwald, B., Mohs, R.C., Mathé, A.A., Johns, C.A., Horvath, T.B., 1986. Cortisol and Alzheimer's disease: I. Basal studies. *Am J Psychiatry*.

de Kloet, E.R., Joels, M., Holsboer, F., 2005. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci* 6(6), 463-475.

De Leon, M., Mcrae, T., Tsai, J., George, A., Marcus, D., Freedman, M., Wolf, A., Mcewen, B., 1988. Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy. *The Lancet* 332(8607), 391-392.

Echouffo-Tcheugui, J.B., Conner, S.C., Himali, J.J., Maillard, P., DeCarli, C.S., Beiser, A.S., Vasan, R.S., Seshadri, S., 2018. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. *Neurology* 91(21), e1961-e1970.

Ferrari, E., Magri, F., Dori, D., Migliorati, G., Nescis, T., Molla, G., Fioravanti, M., Solerte, S.B., 1995. Neuroendocrine correlates of the aging brain in humans. *Neuroendocrinology* 61(4), 464-470.

Ferrari, E., Mirani, M., Barili, L., Falvo, F., Solerte, S., Cravello, L., Pini, L., Magri, F., 2004. Cognitive and affective disorders in the elderly: a neuroendocrine study. *Archives of Gerontology and Geriatrics* 38, 171-182.

Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., Van Der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 33(3), 341-355.

Gallagher, P., Leitch, M.M., Massey, A.E., McAllister-Williams, R.H., Young, A.H., 2006. Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. *Journal of Psychopharmacology* 20(5), 643-649.

Gallagher, P., Watson, S., Smith, M.S., Young, A.H., Ferrier, I.N., 2007. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. *Schizophrenia research* 90(1-3), 258-265.

Geerlings, M.I., Sigurdsson, S., Eiriksdottir, G., Garcia, M.E., Harris, T.B., Gudnason, V., Launer, L.J., 2015. Salivary cortisol, brain volumes, and cognition in community-dwelling elderly without dementia. *Neurology* 85(11), 976-983.

Habib, G.S., 2009. Systemic effects of intra-articular corticosteroids. *Clin Rheumatol* 28(7), 749-756.

Hendren, R.L., De Backer, I., Pandina, G.J., 2000. Review of neuroimaging studies of child and adolescent psychiatric disorders from the past 10 years. *Journal of the American Academy of Child & Adolescent Psychiatry* 39(7), 815-828.

Hengge, U.R., Ruzicka, T., Schwartz, R.A., Cork, M.J., 2006. Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* 54(1), 1-15; quiz 16-18.

Hinterberger, M., Zehetmayer, S., Jungwirth, S., Huber, K., Krugluger, W., Leitha, T., Krampla, W., Tragl, K.H., Fischer, P., 2013. High Cortisol and Low Folate Are the Only Routine Blood Tests Predicting Probable Alzheimer's Disease After Age 75—Results of the Vienna Transdanube Aging Study. *Journal of the American Geriatrics Society* 61(4), 648-651.

Huang, C.W., Lui, C.C., Chang, W.N., Lu, C.H., Wang, Y.L., Chang, C.C., 2009. Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. *J Clin Neurosci* 16(10), 1283-1286.

Jack, C.R., Bernstein, M.A., Borowski, B.J., Gunter, J.L., Fox, N.C., Thompson, P.M., Schuff, N., Krueger, G., Killiany, R.J., DeCarli, C.S., 2010. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. *Alzheimer's & Dementia* 6(3), 212-220.

Janssen, J., Hulshoff Pol, H.E., Lampe, I.K., Schnack, H.G., de Leeuw, F.E., Kahn, R.S., Heeren, T.J., 2004. Hippocampal changes and white matter lesions in early-onset depression. *Biol Psychiatry* 56(11), 825-831.

Johnstone, E., Frith, C., Crow, T., Husband, J., Kreel, L., 1976. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. *The Lancet* 308(7992), 924-926.

Kim, S., Swaminathan, S., Inlow, M., Risacher, S.L., Nho, K., Shen, L., Foroud, T.M., Petersen, R.C., Aisen, P.S., Soares, H., 2013. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. *PLoS One* 8(7), e70269.

Kronenberg, G., van Elst, L.T., Regen, F., Deuschle, M., Heuser, I., Colla, M., 2009. Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression. *J Psychiatr Res* 43(13), 1112-1117.

Lazar, S.W., Kerr, C.E., Wasserman, R.H., Gray, J.R., Greve, D.N., Treadway, M.T., McGarvey, M., Quinn, B.T., Dusek, J.A., Benson, H., 2005. Meditation experience is associated with increased cortical thickness. *Neuroreport* 16(17), 1893.

Le Fevre, M., Matheny, J., Kolt, G.S., 2003. Eustress, distress, and interpretation in occupational stress. *Journal of Managerial psychology* 18(7), 726-744.

Linkowski, P., Mendlewicz, J., Kerkhofs, M., Leclercq, R., GOLSTEIN, J., BRASSEUR, M., Copinschi, G., CAUTER, E.V., 1987. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. *The Journal of Clinical Endocrinology & Metabolism* 65(1), 141-152.

Lipworth, B.J., 1999. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med* 159(9), 941-955.

Lupien, S.J., de Leon, M., De Santi, S., Convit, A., Tarshish, C., Nair, N.P.V., Thakur, M., McEwen, B.S., Hauger, R.L., Meaney, M.J., 1998. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. *Nature neuroscience* 1(1), 69-73.

MacLulich, A.M., Deary, I.J., Starr, J.M., Ferguson, K.J., Wardlaw, J.M., Seckl, J.R., 2005. Plasma cortisol levels, brain volumes and cognition in healthy elderly men. *Psychoneuroendocrinology* 30(5), 505-515.

Macritchie, K.A., Gallagher, P., Lloyd, A.J., Bastin, M.E., Vasudev, K., Marshall, I., Wardlaw, J.M., Ferrier, I.N., Moore, P.B., Young, A.H., 2013. Periventricular white matter integrity and cortisol levels in healthy controls and in euthymic patients with bipolar disorder: an exploratory analysis. *Journal of affective disorders* 148(2), 249-255.

Malberg, J.E., Eisch, A.J., Nestler, E.J., Duman, R.S., 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *Journal of Neuroscience* 20(24), 9104-9110.

Malykhin, N., Travis, S., Sereshki, A.A., Coupland, N., Silverstone, P., Hegadoren, K., Huang, Y., Fujiwara, E., Seres, P., Carter, R., 2018. 132. Effects of Cortisol on Hippocampal Subfields and Centromedial Amygdala Volumes in Healthy Subjects and Patients With Major Depressive Disorder. *Biol Psychiatry* 83(9), S54.

Martignoni, E., Petraglia, F., Costa, A., Bono, G., Genazzani, A.R., Nappi, G., 1990. Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. *Acta Neurol Scand* 81(5), 452-456.

McEwen, B.S., 2012. Brain on stress: how the social environment gets under the skin. *Proc Natl Acad Sci U S A* 109 Suppl 2, 17180-17185.

Mervaala, E., Föhr, J., Könönen, M., Valkonen-Korhonen, M., Vainio, P., Partanen, K., Partanen, J., Tiitonen, J., Viinamäki, H., Karjalainen, A.-K., 2000. Quantitative MRI of the hippocampus and amygdala in severe depression. *Psychol Med* 30(1), 117-125.

Mitra, R., Jadhav, S., McEwen, B.S., Vyas, A., Chattarji, S., 2005. Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. *Proceedings of the National Academy of Sciences* 102(26), 9371-9376.

Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C., Jagust, W., Trojanowski, J.Q., Toga, A.W., Beckett, L., 2005. The Alzheimer's disease neuroimaging initiative. *Neuroimaging Clin N Am* 15(4), 869-877, xi-xii.

Otte, C., Hart, S., Neylan, T.C., Marmar, C.R., Yaffe, K., Mohr, D.C., 2005. A meta-analysis of cortisol response to challenge in human aging: importance of gender. *Psychoneuroendocrinology* 30(1), 80-91.

Plotsky, P.M., Owens, M.J., Nemeroff, C.B., 1995. Neuropeptide alterations in mood disorders. *Psychopharmacology: The fourth generation of progress*, 971-981.

Pratt, L.A., 2009. Serious psychological distress, as measured by the K6, and mortality. *Annals of epidemiology* 19(3), 202-209.

Pruessner, J.C., Dedovic, K., Pruessner, M., Lord, C., Buss, C., Collins, L., Dagher, A., Lupien, S.J., 2010. Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations-2008 Curt Richter Award Winner. *Psychoneuroendocrinology* 35(1), 179-191.

Risacher, S.L., WuDunn, D., Pepin, S.M., MaGee, T.R., McDonald, B.C., Flashman, L.A., Wishart, H.A., Pixley, H.S., Rabin, L.A., Paré, N., 2013. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. *Neurobiol Aging* 34(4), 1133-1144.

Ryan, M.C., Sharifi, N., Condren, R., Thakore, J.H., 2004. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. *Psychoneuroendocrinology* 29(8), 1065-1070.

Sapolsky, R.M., 1996. Why stress is bad for your brain. *Science* 273(5276), 749-750.

Saykin, A., Wishart, H., Rabin, L., Santulli, R., Flashman, L., West, J., McHugh, T., Mamourian, A., 2006. Older adults with cognitive complaints show brain atrophy similar to that of amnesic MCI. *Neurology* 67(5), 834-842.

Schmaal, L., Veltman, D.J., van Erp, T.G., Sämann, P., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., Niessen, W., 2016. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Molecular psychiatry* 21(6), 806-812.

Starkman, M.N., Gebarski, S.S., Berent, S., Schteingart, D.E., 1992. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. *Biol Psychiatry* 32(9), 756-765.

Swaab, D.F., Bao, A.M., Lucassen, P.J., 2005. The stress system in the human brain in depression and neurodegeneration. *Ageing Res Rev* 4(2), 141-194.

Tessner, K.D., Walker, E.F., Hochman, K., Hamann, S., 2006. Cortisol responses of healthy volunteers undergoing magnetic resonance imaging. *Hum Brain Mapp* 27(11), 889-895.

van Erp, T.G., Hibar, D.P., Rasmussen, J.M., Glahn, D.C., Pearlson, G.D., Andreassen, O.A., Agartz, I., Westlye, L.T., Haukvik, U.K., Dale, A.M., 2016. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular psychiatry* 21(4), 547.

Wagner, A., Greer, P., Bailer, U.F., Frank, G.K., Henry, S.E., Putnam, K., Meltzer, C.C., Ziolk, S.K., Hoge, J., McConaha, C., 2006. Normal brain tissue volumes after long-term recovery in anorexia and bulimia nervosa. *Biol Psychiatry* 59(3), 291-293.

Wang, Q., Joels, M., Swaab, D., Lucassen, P., 2012. Hippocampal GR expression is increased in elderly depressed females. *Neuropharmacology* 62(1), 527-533.

Wang, Q., Verweij, E., Krugers, H., Joels, M., Swaab, D.F., Lucassen, P., 2014. Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients. *Brain Structure and Function* 219(5), 1615-1626.

Zvěřová, M., Fišar, Z., Jiráček, R., Kitzlerová, E., Hroudová, J., Raboch, J., 2013. Plasma cortisol in Alzheimer's disease with or without depressive symptoms. *Medical Science Monitor* 19, 681-689.